Drugs / Recombinant Human Choriogonadotropin (r-hCG)
Recombinant Human Choriogonadotropin (r-hCG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01079949 Background | Nov 2007 → Oct 2010 | female infertility | Merck KGaA, Darmstadt, Germany | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT01185704 Background | Nov 2008 → Oct 2011 | polycystic ovary syndrome | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00298025 Background | Sep 2003 → May 2004 | — | EMD Serono | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Choriogonadotropin (r-hCG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01079949 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Choriogonadotropin (r-hCG)” NCT00298025 ↗ |
| Route | Subcutaneous | “250-500 microgram (mcg) subcutaneously” NCT01079949 ↗ |